ATAI Life Sciences/ATAI

$1.85

-3.66%
-
1D1W1MYTD1YMAX

About ATAI Life Sciences

ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

Ticker

ATAI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Florian Brand

Employees

83

Headquarters

Berlin, Germany
Website
atai.life

ATAI Metrics

BasicAdvanced
$328.73M
Market cap
-
P/E ratio
-$0.28
EPS
-
Beta
-
Dividend rate
$328.73M
$2.85
$1.03
1.63M
9.224
7.358
7.358
-169.33%
-13.46%
-15.97%
-14.59%
1,046.918
1.353
1.353
35.34%
70.91%

What the Analysts think about ATAI

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
477.3% upside
High $21.00
Low $5.10
$1.85
Current price
$10.68
Average price target

ATAI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-18.2M
-141.18%
Profit margin
0%
-

ATAI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 26.53%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.21
-$0.21
$0.25
-$0.12
-
Expected
-$0.21
-$0.21
-$0.20
-$0.16
-$0.18
Surprise
-1.18%
1.23%
-224.11%
-26.53%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ATAI Life Sciences stock?

ATAI Life Sciences (ATAI) has a market cap of $317.11M as of April 20, 2024.

What is the P/E ratio for ATAI Life Sciences stock?

The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of April 20, 2024.

Does ATAI Life Sciences stock pay dividends?

No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next ATAI Life Sciences dividend payment date?

ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.

What is the beta indicator for ATAI Life Sciences?

ATAI Life Sciences (ATAI) does not currently have a Beta indicator.

What is the ATAI Life Sciences stock price target?

The target price for ATAI Life Sciences (ATAI) stock is $10.68, which is 477.3% above the current price of $1.85. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ATAI Life Sciences stock

Buy or sell ATAI Life Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing